Close

Serum Institute of India COVID-19 Vaccine advances to trial for phase-III on 1500 Indian patients

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

Top Small Molecule API Partners for 2026

Choosing a small-molecule API manufacturing partner affects cost and...

Roche and Earendil Forge $1.5 Billion Bispecific Antibody Discovery Deal

Roche-owned Genentech has entered into a major collaboration with...
- Advertisement -

Serum institute has completed phase II-B3 trails and will commence phase-III trail after clearances. The third phase trail will be tested on 1500 patients at 14 locations. Balram Bhargava, Director general of the Indian Council of Medical Research, said, “The testing will not be random and will only be tested on those who show COVID-19 symptoms.”

The Oxford vaccine is in the most advanced stages of being developed, and is predicted release in the next two months.

Zycov D and Bharat have cleared phase 1 trails on humans. Zydus Cadila says it may be able to launch the vaccine by next year. Researchers continue efforts on releasing COVID vaccines.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Latest stories

Related stories

Top Small Molecule API Partners for 2026

Choosing a small-molecule API manufacturing partner affects cost and...

Roche and Earendil Forge $1.5 Billion Bispecific Antibody Discovery Deal

Roche-owned Genentech has entered into a major collaboration with...

Treatment for Rare Disease cALD Approved by European Commission

Neuraxpharm and Minoryx Therapeutics have secured European Commission approval...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »